Overview

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Status:
Completed

Trial end date:
2007-11-01

Target enrollment:

Participant gender:

Summary

This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Irbesartan